EWTX
Edgewise Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow -24.9% ·
net new positions +20.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 735.20K | $29.85M | +1 | n/a |
| Q2 2026 | 88 | +9 | 40.35M | $1.62B | +14 | −4 |
| Q1 2026 | 81 | +4 | 39.90M | $1.24B | +9 | −6 |
| Q4 2025 | 77 | +2 | 40.83M | $1.01B | +3 | n/a |
| Q3 2025 | 14 | +1 | 17.98M | $291.62M | +1 | −1 |
| Q2 2025 | 11 | -4 | 17.73M | $232.39M | n/a | −4 |
| Q1 2025 | 12 | -2 | 5.61M | $123.36M | n/a | −2 |
| Q4 2024 | 14 | 0 | 7.38M | $197.14M | +1 | −1 |
| Q3 2024 | 13 | +3 | 6.24M | $166.42M | +3 | n/a |
| Q2 2024 | 10 | n/a | 8.30M | $149.57M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.60M | -4.4% | $42.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Viking Global Investors ✦ | 1.48M | 0.0% | $39.53M | 0.1% | Held | 2 | SEC ↗ |
| 3 | Millennium Management ✦ | 987.03K | -13.8% | $26.34M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 577.57K | +38.9% | $15.42M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 538.25K | -77.1% | $14.37M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 455.35K | +46.2% | $12.15M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 261.46K | -27.9% | $6.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 205.32K | -58.4% | $5.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 9 | Norges Bank ✦ (passive) | 47.76K | New | $1.27M | 0.0% | New | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 27.46K | New | $733,041 | 0.0% | New | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 23.81K | +3.1% | $636,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 21.51K | -56.6% | $574,075 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 8.95K | New | $238,769 | 0.0% | New | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Norges Bank | $1.27M | 0.0% |
| Renaissance Technologies | $733,041 | 0.0% |
| AQR Capital Management | $238,769 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 213 holders, 118.39M shares, $3.71B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.92K sh · $126,704
Officer · 2.17K sh · $95,075
Officer · 304 sh · $13,529
Officer · 150 sh · $6,666
Officer · 2.48K sh · $108,154
Officer · 2.84K sh · $124,303
Officer · 2.78K sh · $121,463
Officer · 104 sh · $4,620
Officer · 800 sh · $35,614
Officer, Director · 8.28K sh · $361,315
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology